SKINBIOTHERAPEUTICS PLC – Appointment Of Interim Cfo
RNS Number : 8088R SkinBioTherapeutics PLC 24 August 2026 SkinBioTherapeutics plc (“SkinBioTherapeutics” or “the Company” or the
RNS Number : 8088R SkinBioTherapeutics PLC 24 August 2026 SkinBioTherapeutics plc (“SkinBioTherapeutics” or “the Company” or the
Manchester, UK – 15 March 2021 – SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, announces its unaudited half year consolidated results for the six months to 31 December 2020.
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces its full year audited results for the year to 30 June 2020.
SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”) a life sciences company focused on skin health, has announced its full year audited results for the year to 30 June 2019.
SkinBioTherapeutics plc (AIM: SBTX), a life sciences company focused on skin health, announces changes to its Board and executive team and provides a business update.
SkinBioTherapeutics plc (AIM: SBTX), a life sciences company focused on skin health, announces the appointment of Stuart John Ashman to the Board as an Executive Director with effect from 18 April 2019.
SkinBioTherapeutics plc (AIM: SBTX), a life sciences company focused on skin health, announces the appointment of Stuart Ashman as an Executive Director of the Company, subject to the completion of regulatory due diligence checks.
SkinBioTherapeutics plc (AIM: SBTX) a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2018.
SkinBioTherapeutics plc (AIM: SBTX) a life sciences company focused on skin health, has announced its full year audited results for the year to 30 June 2018.
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, is pleased to provide a business update.